ArticleFrontiers in pharmacology2026
Post-marketing safety of tarlatamab in small cell lung cancer based on FAERS and WHO-VigiAccess with SHAP-based interpretable machine learning analysis of immune-related adverse events.
Yingyong Ou et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.